Smell loss is an early indicator of infectious and neurodegenerative disorders. In COVID-19, for example, objective smell loss may occur in >90% of patients. Though molecular (PCR) tests are effective in diagnosing SARS-CoV-2 infection, with moderate sensitivity and high specificity, they typically are costly (>$50), with long turnaround times (up to 5-7 days) and have not been as effective in controlling asymptomatic spread. The Aromha Smell Test complements molecular tests with high sensitivity and negative predictive value and can be scaled quickly to provide an important new tool to prevent community spread of COVID, with an at-home, non-invasive, safe, and cost-effective screening test that provides instantaneous results. This platform technology, developed based on 20 years of olfactory research at Harvard, can also be utilized to provide an early signal and improve care in critical neurodegenerative diseases such as Alzheimer's, Parkinson's Disease, and Traumatic Brain Injury.
Operating rooms are often not efficient and are costly to hospitals. Solutions to increasing efficiency neglect to monitor errors in real time which can be stopped and improve efficiency from the time of the incident. This technology pairs artificial intelligence with real time monitoring of operating room procedures to increase efficiency of hospital operating rooms.
Singularity Energy, a cutting-edge grid decarbonization platform, developed by experts from Harvard, MIT, and Johns Hopkins, successfully closed a $4.5 million Seed Round with contributions from Spero Ventures and Energy Impact Partners, among others on January 27, 2022. Their platform, backed by real-time carbon dioxide signals, optimizes energy resources through carbon forecasting and optimization algorithms, enabling companies to balance emissions management and economic benefits. They recently welcomed Tesla co-founder and Spero Ventures partner Marc Tarpening to their board of directors. Singularity Energy has forged alliances with the New York Power Authority & EPRI and also obtained a $1.2 million NSF Grant in May 2022.
Ear infections are the number one cause of doctors visits worldwide, affecting 700 million people each year. Chronic ear infections are often treated with the insertion of a tympanostomy tube into the ear drum. While these help to drain fluid, they often come with complications which can result in follow up surgeries and hearing loss. The PionEar tympanostomy tube technology addresses the most common complications by changing the geometry and materials of the tube to enhance fluid transport and reduce the chances of biofilm formation.
Update 10.22 - Limax has raised $2m in funding, which supported the launch of topical and internal hemostat programs. The company is seeking $6m in seed funding to support first human trials, followed by a $12m series A round to support clinical trials and commercial launch. Limax Biosciences has developed a biodegradable adhesive hydrogel for advanced bleeding with strong and rapid adhesion to wet tissue surfaces. According to Limax CEO Ben Freedman, 30% to 50% of surgeries today are associated with bleeding-related complications, costing the health system between $10,000 and $15,000 per case in hospitalization and prolonged hospital stays.Wounds outside and inside the body are common and can be devastating. Wound adhesives have not been able to compete with suturing due to lack of strength and flexibility. LiMAX has developed a gel adhesive using biomimicry which is able to outperform existing medical adhesives in strength and flexibility.